Tretinoin
Retin-A / all-trans retinoic acid
Tretinoin (Retin-A / all-trans retinoic acid) is a healing & recovery research compound. Binds retinoic acid receptors, normalizing keratinocyte turnover and stimulating dermal collagen synthesis. The most evidence-backed topical for photoageing that exists.
Tretinoin quick facts
| Reported research dose | 0.025–0.1% cream nightly |
| Route | Topical |
| Frequency | Start 2–3x weekly, build to nightly |
| Half-life | Local — effect is on the tissue, not systemic |
| Forms | Topical |
| Evidence level | The strongest topical anti-ageing and acne dataset available |
Also boosts absorption of anything applied with it, which is why it appears in hair-loss combination formulas alongside minoxidil. Retinization — peeling, redness, irritation for 2–6 weeks — is expected; build up slowly rather than pushing through. ⚠️ Photosensitizing, so nightly only and sunscreen daily. Contraindicated in pregnancy.
How Tretinoin works
Binds retinoic acid receptors, normalizing keratinocyte turnover and stimulating dermal collagen synthesis. The most evidence-backed topical for photoageing that exists.
Proposed benefits
Clearer skin and smoother, more even texture — the topical retinoid approved for acne, and separately for the fine wrinkles, mottled pigmentation and roughness of sun-damaged skin. It normalizes how skin cells turn over and drives new collagen in the dermis, so it works on the tissue over months rather than on the surface.
Where to get Tretinoin
Buy Tretinoin at AlgoRx →The evidence for Tretinoin
Graded by what exists behind each claim.
✅ Clinically validated
- One of the most thoroughly evidenced topicals in dermatology. Decades of randomized data for acne and photoageing, including trials showing increased collagen synthesis and reduced fine wrinkling on biopsy — not just on subjective scales.
📊 Correlative data
- Enormous long-term use. The universally reported pattern is the retinization period — irritation, peeling and often an initial acne flare for 4–12 weeks — which is the single most common reason people stop before it works.
🧪 Theoretical / extrapolated
- All-trans retinoic acid binds nuclear retinoic acid receptors and directly alters gene transcription — increasing keratinocyte turnover, normalizing follicular keratinization and stimulating collagen.
- Acting at the level of transcription is why it takes months and why the changes are structural rather than cosmetic. It also predicts the photosensitivity and the absolute contraindication in pregnancy.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Tretinoin actually does
Tretinoin is all-trans retinoic acid, which is not a moisturizer, an exfoliant or an acid in the peeling sense. It is a nuclear hormone receptor ligand, and everything the skin does afterwards is transcription. Retinoic acid enters the keratinocyte, is carried to the nucleus, and binds retinoic acid receptors RAR-alpha, -beta and -gamma. Each RAR heterodimerizes with a retinoid X receptor, the dimer sits on retinoic acid response elements in target promoters, corepressor complexes are exchanged for coactivators, and a gene program runs. The visible result is the histology catching up with a transcriptional instruction given weeks earlier, which is why nothing happens for a month.
The program has two halves, and the second is the one that explains the anti-aging claim. The building half raises procollagen I and III synthesis in the dermis and thickens the viable epidermis. The blocking half suppresses activator protein-1, the transcription factor that ultraviolet light activates and that drives matrix metalloproteinase-1 — interstitial collagenase. So a retinoid both builds collagen and turns down the enzyme that cuts it. Photoaging is largely MMP-mediated collagen loss, which is why a retinoid works on photoaging specifically rather than on aging in general Milosheska 2022.
And here is the mechanism that explains the plateau, which almost no consumer page mentions: retinoic acid induces the enzyme that destroys it. CYP26 is a family of retinoic acid 4-hydroxylases expressed in skin, and retinoic acid is their inducer. Apply retinoic acid and you upregulate its own catabolism locally — a negative feedback loop built into the tissue. That is why escalating the concentration has diminishing returns, and it is the explicit target of a whole line of formulation work: one study built its approach on enhancing RAR activity while inhibiting the hydroxylation of retinoic acid, and tested it on photoaging Kang 2022. The rate-limiting step in a retinoid routine is often not how much you apply, it is how fast the skin is destroying it.
The irritation is the same program, not a separate problem. Retinoid dermatitis — the stinging, flaking and erythema of the first weeks — is accelerated keratinocyte turnover and a transiently disordered barrier while the tissue re-equilibrates at a new set point. It is a mechanistic consequence of the same transcriptional change that produces the benefit, which is why tolerance builds and why stopping and restarting resets the clock.
Cell, rodent, human — and where it stops
Step one, receptor and cell biology, which is settled. The RAR/RXR architecture, the response elements and the AP-1 antagonism are textbook, and the vitamin A system's forms, sources and kinetics are documented in detail Carazo 2021.
Step two, in people, and this is the unusual Vault page where human randomized evidence is the ABUNDANT part. A systematic review screened 180 studies and included 7 randomized controlled trials of topical tretinoin for photoaging, with concentrations from 0.025% to 5% and durations from 3 months to 24 months. All of them reported improvement in the clinical appearance of photoaging including wrinkles and hyperpigmentation, with benefit appearing as early as 1 month and persisting after 24 months Sitohang 2022. That is a rare shape for this site: not a mechanism looking for a trial, but a trial base several decades deep.
Step three, the frontier, which is formulation rather than molecule. Retinoid work has moved to nanoformulations and to delivery vehicles that trade irritation against potency Milosheska 2022, to CYP26-aware designs Kang 2022, and to natural retinol analogs tested from cell culture through to clinical endpoints Brown 2023. The molecule is not being improved; the delivery is.
The obstacle, named — and it is not efficacy. The unresolved question for topical tretinoin is systemic exposure under real-world use. Everyone repeats that percutaneous absorption is minimal, and the pharmacology supports it: retinoic acid is already an endogenous molecule with a regulated plasma concentration, and the skin catabolizes it locally through CYP26 before much can reach the circulation. But the trials that measured plasma retinoic acid used defined areas and defined amounts. Whole-face nightly application of 0.1% for years, under occlusive moisturizer, on inflamed or compromised skin, is the actual use pattern and it is not the studied one. That is the gap.
Tretinoin pharmacokinetics — how much of it actually gets in
The card says the effect is local rather than systemic. That is almost certainly right and it is worth showing the arithmetic instead of asserting it.
What degrades it, and where. Retinoic acid is inactivated by CYP26A1 and CYP26B1 — cytochrome P450 enzymes whose substrate specificity is retinoic acid itself — through 4-hydroxylation, followed by further oxidation and glucuronidation for excretion Carazo 2021. The critical point is where: CYP26 is expressed in the skin, so the drug is catabolized largely at the site of application rather than after reaching the liver. That is what makes a topical retinoid topical, and it is also the feedback loop that caps its own effect Kang 2022.
The barrier, which here is the stratum corneum rather than the gut. The rate-limiting step is diffusion through a lipid-rich, dead, keratinized layer. Anything that changes that layer changes the delivered dose: occlusion increases it, damaged or inflamed skin increases it, a larger treated area increases the total absorbed amount proportionally. There is no first-pass metabolism protecting the reader here, because there is no portal circulation involved — what crosses the skin enters the systemic circulation directly. That is the opposite of the oral situation and it is why area matters more than concentration.
Numbers, so the claim is checkable. Endogenous plasma all-trans retinoic acid sits in the low nanomolar range and is tightly regulated Carazo 2021. A pea-sized 0.05% application to a face is on the order of 250 micrograms of drug delivered to the skin surface; single-digit percentage absorption across intact stratum corneum, distributed into body water and then catabolized, gives a systemic increment that is small against the endogenous pool. The arithmetic supports the claim. It does not survive multiplying the area by ten or the absorption by five, and both are things real users do.
The comparator that makes the point. Oral isotretinoin, a related retinoid taken by mouth, produces a plasma exposure orders of magnitude above endogenous and has a systemic signature everyone recognizes: raised triglycerides, raised transaminases and unequivocal teratogenicity. Topical tretinoin at label use does not produce that signature — and that absence is the strongest available evidence that systemic exposure is genuinely low, because it is an observation about millions of users rather than an estimate.
What would have to be true, and how you would know it was not
Three predictions. The first two test whether the “local, not systemic” claim survives real-world use; the third argues against escalating.
1. Plasma retinol and vitamin A status should not move, and that is the direct test of the local claim. Draw retinol at baseline and after 6 months of nightly whole-face use. Prediction: unchanged, because the applied dose is small against the endogenous pool and is catabolized in the skin Carazo 2021. A measurable rise in a heavy user — large area, high strength, occluded — would be a genuinely new observation, and it is the measurement that would settle the real-world-use gap. Nobody has published it for the modern use pattern.
2. The lipid panel is the sensitive systemic retinoid marker, and it should stay flat. Systemic retinoids raise triglycerides reliably and early — it is the first thing that moves on oral isotretinoin. So a lipid panel at baseline and 6 months is a cheap, sensitive, indirect assay for systemic retinoid exposure. Prediction: no change on topical use. If triglycerides climb in someone using only a topical retinoid, that is either a systemic exposure nobody expected or a confounder, and either is worth knowing.
3. The prediction that argues against escalating: results should NOT scale with concentration, and the CYP26 loop predicts why. Trials span 0.025% to 5% and all of them worked Sitohang 2022. If local catabolism is inducible and rises with exposure Kang 2022, then above some concentration you are mostly feeding the enzyme. The falsifiable version is a split-face test: one side at 0.025%, the other at 0.1%, standardized photographs at baseline and 6 months, everything else identical. Prediction: the irritation difference is large and the outcome difference is small. That is a test one person can run, and its result would be more useful to most readers than another trial.
What nobody has tested yet
Four things nobody has measured, in a molecule that has been studied for forty years.
Nobody has published plasma retinoic acid under the actual modern use pattern. Whole face, nightly, 0.1%, buffered with an occlusive moisturizer, for years, in people who also take a vitamin A containing multivitamin. Every reassuring absorption study used a defined area and a defined amount for a defined period Carazo 2021. The measurement is a straightforward assay and the population is enormous.
Nobody has tested whether CYP26 induction explains the plateau in a person. The hypothesis is explicit and a formulation strategy has been built on it Kang 2022, but skin CYP26 expression before and after months of use, on a punch biopsy, has not been reported alongside a clinical outcome. That single study would convert a plausible explanation into a mechanism.
Nobody has run the concentration split-face trial. Seven randomized trials exist across a 200-fold concentration range Sitohang 2022 and none of them compared two concentrations on the same face. It is the cheapest unrun experiment in dermatology.
Nobody has quantified the absorption-enhancing effect this page already claims. The card notes that tretinoin boosts absorption of anything applied with it, which is why it appears in hair-loss combinations. That is a real and widely used property — and the magnitude of the enhancement, for a specific co-applied drug, at a specific tretinoin concentration, is not published. Anyone combining it with minoxidil or a topical antiandrogen is dosing the second drug through an unmeasured multiplier.
Tretinoin — its own safety story, not its class's
This molecule's risk story is a barrier, a photosensitivity and a pregnancy question, and only the third is genuinely serious.
The barrier effect is the risk that actually happens. Accelerated turnover transiently disrupts the stratum corneum, which means increased transepidermal water loss, increased penetration of everything else applied to that skin, and increased sensitivity to surfactants, acids and fragrance. That is why the routine matters more than the product: introducing a retinoid and an exfoliating acid in the same week compounds a barrier disruption that either alone would tolerate.
Photosensitivity is real and it cuts in an unexpected direction. A thinned stratum corneum and accelerated turnover increase ultraviolet sensitivity during the adjustment period, which is the practical reason retinoids are used at night. Set against that, retinoids have an established role in the prevention and treatment of skin cancers, particularly in high-risk populations Ramchatesingh 2022 — so the same molecule that transiently increases sun sensitivity is used to reduce keratinocyte cancer risk over the long term. Both are true, and the resolution is sunscreen rather than avoidance of the retinoid.
Pregnancy is the one place where the exposure arithmetic stops being reassuring enough to reason about on a web page. Systemic retinoids are unequivocal teratogens; topical exposure is estimated to be far too low to matter, and that estimate is an estimate under a use pattern that has never been measured in the way described above. When the probability is very low and the consequence is irreversible, the calculation is not the reader's to do from a vault page. This is a question for the clinician managing the pregnancy, and nothing here is medical advice.
What reduces risk here, mechanistically rather than generically. The measures that follow from the pharmacology above: treat AREA as the dose variable, since systemic exposure scales with treated surface rather than with tube strength; apply to dry skin, because damp skin absorbs more and irritates more; do not apply to broken or inflamed skin, where the rate-limiting barrier is gone; and give the CYP26 feedback loop time by holding a concentration for months before escalating, because the trials that worked ran for months at low concentrations Sitohang 2022.
Sources read for this page
- Sitohang IBS, et al. Topical tretinoin for treating photoaging: A systematic review of randomized controlled trials. International Journal of Women's Dermatology 2022 · PMID 35620028
- Milosheska D, et al. Use of Retinoids in Topical Antiaging Treatments: A Focused Review of Clinical Evidence for Conventional and Nanoformulations. Advances in Therapy 2022 · PMID 36220974
- Kang S, et al. Enhancement of Efficacy of Retinoids through Enhancing Retinoid-Induced RAR Activity and Inhibiting Hydroxylation of Retinoic Acid, and Its Clinical Efficacy on Photo-Aging. Pharmaceutics 2022 · PMID 36365229
- Ramchatesingh B, et al. The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review. International Journal of Molecular Sciences 2022 · PMID 36293471
- Carazo A, et al. Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity. Nutrients 2021 · PMID 34069881
- Brown A, et al. Natural Retinol Analogs Potentiate the Effects of Retinal on Aged and Photodamaged Skin: Results from In Vitro to Clinical Studies. Dermatology and Therapy (Heidelberg) 2023 · PMID 37615835
Tretinoin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Tretinoin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
Applied topically, this has no systemic exposure worth speaking of — so there is nothing to interact with anything you take, and no blood marker it could move. That is the honest answer rather than an empty section. The real interactions for a topical are layering ones: what you put on before and after it, and at what pH.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Tretinoin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Tretinoin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
Tretinoin — frequently asked questions
What is Tretinoin?
Tretinoin (Retin-A / all-trans retinoic acid) is a healing & recovery research compound. Binds retinoic acid receptors, normalizing keratinocyte turnover and stimulating dermal collagen synthesis. The most evidence-backed topical for photoageing that exists.
Is the full Tretinoin protocol on this page?
The reported research dose is on this page, along with how Tretinoin works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Tretinoin?
Tretinoin has an approximate half-life of Local — effect is on the tissue, not systemic, which is part of what determines how often it's dosed.
What's the evidence behind Tretinoin?
Current evidence level: The strongest topical anti-ageing and acne dataset available. Tretinoin is offered for research purposes only and is not an approved medicine.
Tretinoin inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Tretinoin is used for
Tretinoin appears under 1 goal in the goal router.
Related Healing & Recovery compounds
Where this goes next
Tretinoin is the collagen arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.